rs1279683 — SLC23A2

SLC23A2 rs1279683 — Vitamin C Delivery, Glaucoma Risk, and the SVCT2 Transporter

Vitamin C cannot synthesize itself — it must be obtained from food, absorbed by the gut, and then actively transported into individual cells. That last step is controlled by SVCT2¹¹ SVCT2
Sodium-dependent Vitamin C Transporter 2, encoded by SLC23A2 — the primary transporter moving ascorbate from the bloodstream into metabolically demanding tissues such as the brain, adrenal glands, and eyes. A common intronic variant at rs1279683 in SLC23A2 has been associated with meaningfully lower plasma vitamin C concentrations and a 67% increased risk of primary open-angle glaucoma in carriers of the G allele. Because SVCT2 is the dominant transporter for the retina, brain, and adrenal cortex — tissues that concentrate ascorbate to levels 10–100 times higher than plasma — this variant sits at the intersection of antioxidant defence, intraocular pressure regulation, and cognitive resilience.

The Mechanism

rs1279683 falls within an intron of SLC23A2 on chromosome 20 (GRCh38 position 5,002,446). SLC23A2 is transcribed from the minus strand. The variant's functional consequence is not characterized by in vitro assay, but intronic variants can alter pre-mRNA splicing efficiency²² pre-mRNA splicing efficiency
Intronic variants near splice regulatory elements or branch points can disrupt the recognition signals needed to join exons correctly, potentially reducing transporter protein output, local enhancer/silencer activity, or mRNA stability. The measurable reduction in plasma ascorbate in G allele carriers implies that this intronic position does influence SVCT2 expression or function in a detectable way.

SVCT2 is most highly expressed in the adrenal gland (RPKM 40.7) and brain (RPKM 20.8). It is the sole active transporter moving ascorbate across the blood-brain barrier and into the retinal ganglion cells. In the aqueous humor of the eye, ascorbate is present at concentrations up to 20-fold higher than plasma — a gradient maintained by SVCT2 activity in ciliary epithelial cells. That gradient is protective against oxidative damage to the trabecular meshwork, which regulates intraocular pressure. Reduced SVCT2 efficiency compresses this protective gradient and may contribute to glaucoma pathogenesis.

The Evidence

The strongest direct evidence comes from a Spanish case-control study³³ Spanish case-control study
Zanon-Moreno V et al. Association between a SLC23A2 gene variation, plasma vitamin C levels, and risk of glaucoma in a Mediterranean population. Mol Vis, 2011 of 150 POAG cases and 150 controls. GG homozygotes had plasma vitamin C of 9.0 ± 1.4 µg/ml in cases compared to 10.5 ± 1.6 µg/ml in non-GG genotypes — a statistically significant 14% reduction. Among controls, GG subjects showed 10.9 vs 12.1 µg/ml. The GG genotype conferred an age- and sex-adjusted odds ratio for POAG of 1.67 (95% CI 1.03–2.71, p = 0.010).

The glaucoma association was replicated across a larger evidence base. A meta-analysis of 108 case-control studies⁴⁴ meta-analysis of 108 case-control studies
Chen M et al. Association of Gene Polymorphisms With Primary Open Angle Glaucoma: A Systematic Review and Meta-Analysis. Invest Ophthalmol Vis Sci, 2019 covering 35,389 POAG patients and 51,742 controls identified rs1279683 among 20 SNPs in 12 genes with consistent genome-wide significance.

A Japanese cohort study of 393 subjects examined vitamin C transporter variants and cognitive decline⁵⁵ vitamin C transporter variants and cognitive decline
Hayashi K et al. Effects of functional variants of vitamin C transporter genes on apolipoprotein E E4-associated risk of cognitive decline: The Nakajima study. PLoS One, 2021. Minor allele carriers (i.e., individuals with at least one A allele) did not show elevated cognitive risk. However, among the subset also carrying APOE4, carrying the minor allele (A) was protective: APOE4 carriers who were GG homozygotes had substantially higher cognitive decline risk (OR 2.02, 95% CI 1.05–3.87) compared to APOE4 carriers with at least one A allele. This finding suggests that adequate vitamin C transport is particularly important for neurological resilience when APOE4-mediated inflammation is present.

Large-scale blood cell GWAS data add a complementary dimension: a trans-ethnic analysis of 746,667 individuals⁶⁶ a trans-ethnic analysis of 746,667 individuals
Chen MH et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. Cell, 2020 identified rs1279683 as a genome-wide significant signal for mean corpuscular volume (MCV, p = 3×10⁻²²) and mean corpuscular hemoglobin (MCH, p = 3×10⁻¹⁹). Vitamin C supports iron absorption and erythropoiesis — impaired SVCT2 function may reduce intracellular ascorbate available to erythroblasts, subtly affecting red cell development.

Practical Actions

The G allele at rs1279683 is the population-common allele, present at ~69% in Europeans, so GG homozygosity affects roughly 1 in 3 people of European descent. The vitamin C deficit is moderate — GG homozygotes in the Zanon-Moreno cohort averaged about 9–11 µg/ml versus 11–12 µg/ml for other genotypes. This is clinically meaningful at the margin: suboptimal plasma vitamin C is defined below ~28 µmol/L (approximately 5 µg/ml), and GG homozygotes cluster at the lower end of the adequate range. Consistently high dietary or supplemental vitamin C intake can offset the reduced transport efficiency by increasing the plasma substrate available for SVCT2.

Glaucoma management for G allele carriers does not replace standard monitoring but adds a modifiable risk factor: regular intraocular pressure measurement and a confirmed adequate vitamin C status. High-dose vitamin C (1,000–2,000 mg/day) has been shown in small trials to reduce intraocular pressure in some individuals; while not yet a clinical standard, it is a low-risk intervention for GG homozygotes with a family history or borderline IOP.

Interactions

rs1279683 acts in parallel with rs6053005, another intronic SLC23A2 variant associated with plasma vitamin C in the EPIC cohort. Both variants influence SVCT2-mediated tissue delivery; their combined effect has not been formally studied but is likely additive given their independent signals in the same gene. rs6133175, an SLC23A2 variant associated with preeclampsia and also independently predictive of plasma vitamin C, is a third independent signal at this locus.

The interaction with APOE4 (rs429358) is the most clinically significant: GG homozygotes who also carry APOE4 face a compounded risk — APOE4 increases neuroinflammation and oxidative burden in the brain while GG reduces the SVCT2 capacity to supply ascorbate for antioxidant defence. This combination warrants particular attention to optimizing vitamin C status. Propose for compound action: GG × APOE4 → augmented vitamin C supplementation and cognitive monitoring.